Metabotropic glutamate receptor group III (mGluR group III)

Metabotropic glutamate receptor group III refers collectively to a subgroup within the metabotropic glutamate receptors that includes four main members—mGluR4 (*GRM4*), mGluR6 (*GRM6*), mGluR7 (*GRM7*), and mGluR8 (*GRM8*)—all belonging to class C G protein-coupled receptors. These receptors are primarily expressed presynaptically throughout the central nervous system where they function as neuromodulators by inhibiting adenylyl cyclase via Gi/o proteins. This action suppresses neuronal excitability through reduced cAMP production. Group III metabotropic glutamate receptors play important roles in regulating synaptic transmission, providing neuroprotection against excitotoxicity and apoptosis, modulating pain pathways, influencing cognitive processes, and potentially affecting psychiatric disorders such as schizophrenia. They have been investigated as therapeutic targets particularly for neurodegenerative diseases like Parkinson’s disease due to their ability to modulate neurotransmission without directly causing widespread excitation or inhibition.

Other names

Group III metabotropic glutamate receptormGluR4, mGluR6, mGluR7, mGluR8 (individual subtypes)Group III mGluRs

Drugs targeting these receptors typically act by: - Agonism at the orthosteric site to activate the receptor and inhibit adenylyl cyclase activity, reducing cAMP signaling - Allosteric modulation to enhance or inhibit endogenous ligand effects at specific subtypes This leads to decreased neurotransmitter release presynaptically and reduced neuronal excitability.